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Abstract: Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and
the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is largely based
upon clinical signs and the use of prostate-specific antigen (PSA) levels. Although PSA levels have
been criticised for a lack of specificity, leading to PC over-diagnosis, it is still the most commonly
used biomarker in PC management. Unfortunately, PC is extremely heterogeneous, and it can be
difficult to stratify patients whose tumours are unlikely to progress from those that are aggressive and
require treatment intensification. Although PC-specific biomarker research has previously focused
on disease diagnosis, there is an unmet clinical need for novel prognostic, predictive and treatment
response biomarkers that can be used to provide a precision medicine approach to PC management.
In particular, the identification of biomarkers at the time of screening/diagnosis that can provide
an indication of disease aggressiveness is perhaps the greatest current unmet clinical need in PC
management. Largely through advances in genomic and proteomic techniques, exciting pre-clinical
and clinical research is continuing to identify potential tissue, blood and urine-based PC-specific
biomarkers that may in the future supplement or replace current standard practices. In this review,
we describe how PC-specific biomarker research is progressing, including the evolution of PSA-
based tests and those novel assays that have gained clinical approval. We also describe alternative
diagnostic biomarkers to PSA, in addition to biomarkers that can predict PC aggressiveness and
biomarkers that can predict response to certain therapies. We believe that novel biomarker research
has the potential to make significant improvements to the clinical management of this disease in the
near future.
Keywords: prostate cancer; precision medicine; tissue-based biomarkers; liquid-based biomarkers
1. Introduction
Prostate cancer (PC) was first reported in 1853 after a histological examination con-
ducted by Dr. J. Adams, a surgeon in The London Hospital [1]. Adams noted in his
description that it was ‘a very rare disease’, a comment that now contrasts greatly to
how significant PC has become in the field of oncology. Worldwide, PC is the second-
most-frequently diagnosed male cancer and the fifth-most-common cause of cancer-related
mortalities. Current estimates indicate that ~1.4 million new cases are diagnosed and
400,000 PC-related deaths occur every year [2]. In the United States of America PC alone
accounts for 26% of cancer diagnoses in men [3], while recently in the United Kingdom
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PC has overtaken breast cancer to become the most commonly diagnosed cancer [4]. PC is
more frequently identified in elderly men, with estimates indicating that ~60% of cases
are diagnosed in those older than 65 years of age [5]. Due to the aging nature of the
global population, it is thought that the social and economic impact of PC will increase
significantly over the coming years.
Prostate Cancer: Risk Classification, Treatment and Challenges
PC is a highly heterogeneous disease with widely varying clinical outcomes. Some PC
patients present with slow growing, localised cancers that do not pose an immediate
risk to overall health. These patients may never go onto develop clinical symptoms, and
in the absence of screening programmes they would never have known that they had
PC [6]. Other tumours, however, can grow rapidly, resist treatment, metastasise early
and can be fatal. Knowledge of PC aggressiveness is very important in determining the
most appropriate treatment for each patient. Current methods for stratifying patient risk
involve (i) staging, i.e., determining the extent of the tumour in the body. (ii) Gleason
grading, an indication of cancer aggressiveness based on the architecture or pattern of
the glands within the prostate. Scores range from 1 to 5, with the most common and
second most predominant scores combined to give the final Gleason score (low grade = 6,
intermediate grade = 7, high grade ≥ 8). (iii) The assessment of prostate specific antigen
(PSA) levels. Together, this information is used to determine whether a patient is within a
low-, intermediate- or high-risk group [7]. Typically, tumours will be histologically graded
using needle core biopsy tissue prior to the patient starting treatment. As Gleason grade
continues to be regarded as the greatest predictor of prognosis [8], there is a universal
dependence on biopsy samples for risk assessment and treatment selection. However, there
are many significant limitations associated with the use of tissue biopsies. PC is different
to many other tumour types in that at the time of diagnosis, 60–90% of patients have
multiple, separate and potentially diverse cancer foci scattered throughout the prostate.
These foci can develop independently and can differ in their aggressiveness [9]. Thus,
from a treatment perspective, tumour heterogeneity represents a significant challenge for
biopsy-based assays to determine PC aggressiveness, as it can lead to differences in the
grade observed between the diagnostic biopsy specimen and the final grade based upon
samples acquired following surgery [10]. From the patient’s perspective, the acquisition
of tissue biopsies is an invasive procedure and can lead to side effects that include rectal
bleeding, haematuria, infection and pain [11].
There are a variety of treatment options available to newly diagnosed PC patients [12].
Active surveillance (AS) is one option for low- or favourable-intermediate risk patients; this
involves regular testing to assess whether or not their cancer is growing or spreading. If
there are signs of disease progression, or if a patient is deemed higher risk, then definitive
treatments including radical prostatectomy (RP), radiotherapy (RT) and androgen depriva-
tion therapy (ADT) can be provided. About 87% of patients diagnosed with localised PC
are given some form of radical therapy [13]. Unfortunately, treatments such as RT and RP
can lead to substantial complications (including urinary, bowel and sexual dysfunction),
each of which can significantly affect patient quality of life [14,15].
The focus of PC-specific biomarker research has previously been on disease diagnosis.
There is, however, an increasing clinical need for the identification of novel prognostic,
predictive and treatment response biomarkers that can be used to provide a precision
medicine approach to PC management. Due to the significant complications associated with
definitive treatment, the identification of biomarkers at the time of screening/diagnosis
that provide an indication of the risk of aggressiveness is perhaps currently the greatest
unmet clinical need in PC management. Biomarkers that help fulfil this role would help
clinicians determine the most appropriate treatment strategy for newly diagnosed patients
(i.e., who should be considered for AS and who should undergo radical treatment).
Largely through advances in genomic and proteomic techniques, exciting pre-clinical
and clinical research is continuing to identify potential tissue, blood and urine-based
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PC-specific biomarkers that may in the future supplement or replace current standard
practices. This review will provide an overview of selected biomarkers that have the
potential to increase the likelihood of PC detection, reduce over-diagnosis, predict the risk
of progression and recurrence, and also give an indication of treatment response. We will
begin by discussing PSA, which is unique as a biomarker as it has can be used for both
PC detection, prognosis and to assess the effects of treatment. We will then go onto to
discuss other biomarkers that have a role in the pre-diagnostic and post-diagnostic settings.
Figure 1 and Table 1 outline where and how each of the biomarkers and their associated
tests, discussed in this review, can contribute to PC patient management.
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Table 1. Overview of prostate cancer biomarker assays that are in development or have gained clinical approval. Pre-
diagnostic biomarkers (blue), biomarkers used in biopsy-proven prostate cancer cases (yellow), predictive biomarkers
(green). 3.4mt∆, 3.4-kb mitochondrial genome deletion; AR, androgen receptor; AR-V7, androgen receptor splice variant
7; BCR, biochemical recurrence; CTCs, circulating tumour cells; CTLA-4, cytotoxic T lymphocyte-associated protein-4;
miRNA, microRNAs; PARP, poly (ADP-ribose) polymerase; PC, prostate cancer; PD-1, programmed death-1; PORTOS,
Post-Operative Radiation Therapy Outcomes Score; PTEN, phosphatase and tensin homolog; RP, radical prostatectomy; RT,
radiotherapy; sncRNAs, small non-coding RNAs; TMB, Tumour mutational burden.
Test Analyte Analyte Source Outcome Provided by Test
SelectMDX mRNA Urine Probability of detecting PC after prostatic biopsy,tumour grade
TMPRSS2-ERG score mRNA Urine Probability of detecting PC after prostatic biopsy,tumour grade
miR Sentinel PCa sncRNAs Urine Distinguishes patients with PC from subject withno evidence of PC, tumour grade
ConfirmMDx Methylated DNA Prostatic biopsy tissue Separates patients that have PC from those witha true negative biopsy result, tumour grade
PCA3 mRNA Urine Probability of detecting PC after prostatic biopsy
Prostate Core Mitomic Test 3.4mt∆ Prostatic biopsy tissue Resolves false from true-negative prostaticbiopsy results
Oncotype DX Genomic Prostate
Score mRNA Prostatic biopsy tissue Tumour grade, BCR, metastasis, recurrence
Prolaris mRNA Prostatic biopsy tissue Tumour aggressiveness, metastasis
ProMark Protein Prostatic biopsy tissue Tumour aggressiveness
Decipher mRNA Primary tumour after RP,prostatic biopsy tissue Tumour aggressiveness, BCR, metastasis
miR Sentinel CS/GH tests sncRNAs Urine Tumour grade
Ki67 Protein Primary tumour after RP,prostatic biopsy tissue BCR, metastasis, survival
miR risk score miRNAs Serum Gleason score, BCR
PTEN Protein Prostatic biopsy tissue Gleason score, stage, metastasis, BCR, recurrence
PORTOS mRNA Primary tumour after RP Predict RT response
DNA repair defects mRNA Prostatic biopsy tissue Predict response to PARP inhibitors
AR-V7 Protein, mRNA Prostatic biopsy tissue, CTCs Predict resistance to AR signalling inhibitors orsensitivity to taxanes
CTLA-4 and PD-1 receptors, TMB Protein, mRNA Prostatic biopsy tissue, CTCs Response to immunotherapy
2. Prostate Specific Antigen
Prostate specific antigen (PSA) is a blood-based biomarker that can be used in the
screening of patients for PC detection, in the surveillance of patients following diagno-
sis, to assess the risk of PC recurrence, and for monitoring treatment responses. PSA,
a kallekrein-like serine protease glycoprotein, is encoded by the prostate-specific gene
kallikrein 3 (KLK3) [16]. PSA is secreted by prostatic epithelial cells, with low levels of
this glycoprotein typically present in blood samples from healthy individuals. Its primary
function is to liquefy semen through proteolysis [16]. Although the specific mechanisms are
open to debate, raised PSA levels within the blood of men with PC are not due to amplified
expression of the protein, but instead result from increased release of PSA into the blood
due to the disruption of prostate architecture observed in prostate tumours [17]. While
there is no recognised defined cut-off for diagnosing PC, many clinicians consider PSA
levels≤ 4.0 ng/mL as normal, with higher levels indicating a need for further investigation.
PC patients with unexpectedly high PSA levels have been encountered, with concentrations
as high as 23,126 ng/mL previously reported [18].
2.1. PSA and Screening
In the first large scale investigation of the clinical use of PSA, levels of this protein
were found to be associated with the clinical stage of PC, with increased levels correlated
with more advanced disease stages [19]. Later studies investigated the use of PSA in terms
of its ability to screen the population for disease, with a view to detecting early-stage
PC. These reports highlighted that, when used in conjunction with clinical findings, PSA
levels of ≥4.0 ng/mL resulted in improved PC detection [20–22]. The assessment of PSA
levels was approved by the US Food and Drug Administration (FDA) as a diagnostic
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tool for PC detection in 1994 [23]. Its use as a screening test among asymptomatic men
gained popularity, which in the US alone led to a dramatic increase in PC incidence [24].
The proportion of patients diagnosed at first presentation with metastatic disease also
reduced following its use in screening programmes [24]. However, a significant criticism
of the widespread use of PSA testing in the population was that it led to a PC diagnosis
in men that would never have otherwise been diagnosed with clinically significant PC;
the term “over-diagnosis” is often used to describe this situation [24]. Over-diagnosis, in
relation to PSA screening programmes, has been reported to range from 20–66% [25,26].
Decreasing the number of PC patients diagnosed with later stage disease, while also
increasing the number of patients receiving treatment, led to concerns that PC had become
over-treated [27]. As well as having cost implications, over-treating PC can have significant
effects on the mental and physical health of patients. As previously mentioned, even
diagnostic procedures such as a prostatic biopsy carry risks of complications [11], while the
side effects from RP and RT, which can occur in 50% of patients, can be severe. Recognised
side effects from these treatments include urinary incontinence, sexual dysfunction and
diminished colonic/rectal function [28,29].
Unfortunately, there is still debate on the extent to which PSA screening decreased
PC mortality rates observed in the 1990s. The Cluster Randomised Trial of PSA Testing
for Prostate Cancer (CAP) [30], the European Randomised Study of Screening for Prostate
Cancer (ERSPC) [31,32] and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial (PLCO) [33] were three large randomised prospective trials that assessed the value
of PSA screening in asymptomatic men for PC diagnosis. While the ERSPC trial found
that screening for PC lowered PC-specific mortality and reduced the risk of developing
metastatic disease, the two other trials did not replicate these results. Even though each of
these trials assessed asymptomatic men between 50–60 years old, the trials differed greatly
in their design, with limitations associated with each of them (for example, a screening/no-
screening comparison was not strictly performed in the PLCO trial, as up to 90% of those
in the “control group” had at least one PSA test, either before the screening began or over
the course of the screening period) [34]. A recent systematic review for the US Preventive
Services Task Force (USPSTF) suggested that PSA screening does have the ability to lower
PC mortality risk, but it is linked with false-positive results, complications from resulting
biopsy procedures and over-diagnosis [26].
In 2018, the USPSTF stated that results from screening trials had failed to show
reductions in all-cause mortality and that there was inadequate evidence to suggest a
benefit from PSA screening to decrease PC mortality in men over the age of 70. They also
concluded that the net benefit of PSA-based screening for PC in men between 55–69 years is
small [28]. As a result of the uncertainty over the benefits of PSA in screening, most of the
guidelines that have been published are against mass screening, but advocate screening in
men over 50 years of age with greater than 10 years life expectancy, only after the potential
benefits and harms of screening have been outlined to the patient [28,35–37]. In contrast,
the European Association of Urology and the Memorial Sloan Kettering Cancer Center
both recommend that PSA screening should begin in well-informed men at 45 years of
age, with the interval of testing thereafter dependent on the levels observed in this first
test [38,39].
2.2. PSA and Prognosis
As well as having use in patient screening, PSA levels can also be utilised to estimate
prognosis in newly diagnosed PC patients. In general, the more elevated the PSA levels
are, the poorer the outcome [40–44]. Studies have shown that PSA levels > 20 ng/mL at
diagnosis lead to a significant decrease in 5-year survival rates, with PSA concentrations
above 98 ng/mL leading to a greater than 50% decrease in survival. The authors concluded
that these highly elevated PSA concentrations suggest the presence of more aggressive
or occult metastatic disease, thus indicating that these patients might benefit from more
aggressive treatments [42]. While this relationship between high PSA levels and poor
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prognosis is especially relevant in PC patients with low or intermediate grade PC, in
patients with high grade disease (Gleason score 8–10), lower PSA levels can actually
predict a poorer outcome [45,46]; 10% of PC patients with higher grade disease had PSA
readings of ≤2.5 ng/mL [46]. Additionally, reports have indicated that patients who
present with PSA levels lower than 4 ng/mL have a greater incidence of distant metastasis
than those with PSA concentrations between 4–10 ng/mL, 10–20 ng/mL or >20 ng/mL;
Zheng et al. inferred that clinicians should pay particular attention to those patients
with lower PSA levels, as their disease may be biologically aggressive [43]. Even though
there is a correlation between PSA levels at diagnosis and outcome, PSA has only limited
prognostic accuracy when utilised alone. To improve prognostic accuracy within the clinic,
tumour histological and clinical factors are assessed alongside PSA levels when predicting
outcome [34].
2.3. Use of PSA Following Initial Diagnosis
There are a variety of management options available to patients with newly diagnosed
PC. Regardless of the therapy chosen, PSA levels are commonly analysed following the
instigation of initial definitive treatment(s). The optimal frequency of PSA testing has yet to
be ascertained. After definitive therapy, PSA testing is advised every 6–12 months for the
first 5 years, which can then subsequently be reduced to once a year. PSA testing may be
carried out more regularly in those patients that are at a higher risk of recurrence (Gleason
score 8–10 or PSA > 20 ng/mL) [34]. PSA concentrations observed after therapy differ
depending on the treatment given. Within 2 months of RP in patients with localised PC, PSA
concentrations generally decrease to undetectable levels (<0.1 ng/mL) [34]. Two successive
increasing PSA measurements of >0.2 ng/mL is defined as biochemical recurrence (BCR)
after RP [47]. PSA concentrations reduce more slowly after RT or brachytherapy, with
concentrations of <0.5 ng/mL generally observed 6 months after treatment. Transient
increases in PSA levels may also occur post-RT within 3 years after treatment [48,49].
Increases in PSA levels of 2 ng/mL or more above the PSA nadir (also known as the
Phoenix definition of BCR [50]) is regarded as BCR after RT [51].
The clinical management of patients that exhibit BCR after primary treatment is a
controversial issue [52]. Even though BCR signifies a higher risk of clinical recurrence,
many men remain symptom-free after its manifestation. In one study, only 34% of patients
that exhibited BCR later showed signs of clinical recurrence. In those that did suffer
recurrence, 8 years was the median duration of time between BCR and metastasis, with
an additional median time to death of 5 years [53]. Clinicians therefore face the challenge
of preventing or delaying progression in those patients that are deemed to be at risk,
while also avoiding the over-treatment of men whose disease might never continue past
PSA-only recurrence. There have been attempts to distinguish factors linking BCR to the
risk of clinical recurrence; higher Gleason scores and shorter intervals to BCR have been
associated with recurrence risk after both RP and RT [54].
Because many patients that exhibit BCR never go on to develop signs of clinical
recurrence, there is still debate on whether ADT should be given early, or if clinicians
should delay administration until clinical evidence of disease recurrence is present [55,56].
While an initial study comparing immediate ADT (patients treated within 3 months of PSA
relapse) to deferred ADT (patients treated when they presented with clinical symptoms)
demonstrated that there was no difference in 5 year overall survival rates between the two
groups [57], more recent work indicates that prompt treatment with ADT may lead to better
outcomes [58]. PSA kinetics and time to PSA nadir are important indicators of response
to primary ADT treatment. However, the prognostic significance of PSA kinetics after
primary ADT continues to be controversial. Intuitively, many urologists expected that more
rapid PSA declines in response to primary ADT would be linked with extended survival.
Conversely, reports suggest that these rapid responses to treatment may be indicative
of more aggressive disease [59]. Even though ADT is advantageous in most patients
exhibiting BCR, there are men whose disease will still progress despite treatment. When
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this occurs in the absence of any metastatic disease, it is known as non-metastatic castrate-
resistant prostate cancer (nmCRPC). Castrate-resistant disease is often distinguished by
two successive PSA increases when testosterone levels are <0.5 ng/mL [60].
Whilst the majority of men diagnosed with localised PC may be cured, their risk of
treatment failure and death from subsequent metastatic disease increases significantly with
their risk grouping at diagnosis (for example, at least 50% of all high-risk patients will not
be cured). ADT is the standard initial treatment for those patients that develop distant
metastases [61]. Although sequential PSA measurements can be used to assess response to
ADT, validated definitions of disease progression or response to treatment with regard to
PSA levels have yet to be established for this scenario. However, studies have demonstrated
that advanced PC patients with a PSA measurement of <4 ng/mL after around 7 months
of ADT have an improved outcome compared to patients with PSA levels > 4 ng/mL [62].
Additional studies have similarly shown that lower PSA measurements after ADT lead
to better outcomes [63]. As is the case with localised disease, resistance to ADT also
occurs in the metastatic setting, leading to the formation of metastatic castrate-resistant
prostate cancer (mCRPC). PSA can be utilised to evaluate the response of mCRPC to
treatment [64–67].
3. Techniques to Improve the Diagnostic Accuracy of PC
As previously discussed, over-diagnosis and over-treatment are two well-documented
issues of the use of PSA for screening and monitoring programmes. Richard Albin, who
is credited with the discovery of PSA [68], published “The Great Prostate Hoax” in 2014,
where he discusses how he never intended for his discovery to be used in a PC screening
program, highlighting its two major limitations: (i) it is not cancer-specific and (ii) it cannot
differentiate between slow growing and aggressive cancers. The low specificity of PSA
for detecting disease can lead to a considerable number of men undergoing unnecessary
biopsies in order to exclude or verify the presence of malignancy. This situation arises
largely because various non-cancerous processes such as trauma, prostatitis and benign
prostatic hyperplasia (BPH) can lead to increased serum PSA levels [17]. BPH is a significant
confounding factor for PC diagnosis as the occurrence of this condition increases with
age, with a prevalence of 8%, 50% and 80% reported in men in their 30s, 50s and 80s,
respectively [69]. The number of false positive PSA-based diagnoses will of course depend
on the threshold used. In the ERSCP trial a PSA threshold of ≥3.0 ng/mL was used to
determine if a biopsy was required; approximately 75% of men who presented with PSA
levels ≥ 3.0 ng/mL were confirmed as PC negative following a biopsy procedure [31]. PSA
screening can also suffer from false negative results; it has been estimated that a cut off of
4.0 ng/mL will miss around 15% of PC cases, of which around 15% will have advanced
Gleason scores [70], and that a cut off value of 4.1 ng/mL will only detect ~20% of PC
cases [71]. In an attempt to overcome these limitations, studies have investigated the use of
various PSA parameters/dynamics, along with the use of additional or adjunct tests, to
improve the diagnostic specificity and prognostic potential of PSA (Table 2).
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Table 2. Overview of PSA-based diagnostic and prognostic assays. fPSA, free PSA; hK2, human kallikrein 2; iPSA, intact
PSA; PHI, Prostate Health Index; PSA, prostate specific antigen; SNPs, single nucleotide polymorphisms.
Test Fluid Target
PSA density Serum PSA
PSA dynamics Serum PSA
%fPSA Serum PSA and fPSA
PHI Serum PSA, fPSA, [2]proPSA
4Kscore Serum PSA, fPSA, iPSA, hK2
STHLM3 model Serum PSA, fPSA, iPSA, hK2, beta-microseminoprotein, macrophage inhibitory cytokine 1, 232 SNPs
PSA glycosylation Serum α2,3-sialylated PSA
epiCaPture Urine PSA and methylated GSTP1, SFRP2, IGFBP3, IGFBP7, APC, PTGS2
3.1. PSA Density
PCs can produce increased levels of PSA per volume of tissue compared to benign
prostatic conditions. To take into account prostate volume, PSA density (PSAD) was
introduced in the early 1990s by Benson et al. This was done in an attempt to improve the
accuracy of serum PSA testing to distinguish between small-volume organ-confined PC
and BPH [72]. PSAD is calculated by dividing serum PSA by the volume of the prostate
gland, measured by either transrectal ultrasound or magnetic resonance imaging. Studies
have shown that PSAD has the potential to influence biopsy decisions by helping to identify
men that harbour clinically significant PC [73–76], with PSAD becoming a better marker for
predicting clinically significant PC as PSA levels increase [77]. Further work has exhibited
the potential of PSAD to determine PC aggressiveness and predict the presence of adverse
pathology in patients undergoing RP [78,79]. These results suggest that PSAD may play a
role in risk stratification, which could be especially important when deciding which patients
may be eligible for AS [79–81]. Overall, PSAD represents a simple, inexpensive tool that, if
validated, has the potential to identify patients that may forego unnecessary biopsies.
3.2. PSA Dynamics
Changes in PSA parameters including doubling time (PSADT, time required for PSA
levels to double) and velocity (PSAV, the rate of PSA change/year) can provide additional
information over the evaluation of total PSA alone. Carter et al. introduced the concept of
PSAV in 1992, performing multiple PSA measurements on serum samples obtained from
men between 7–25 years prior to histological diagnosis or exclusion of PC; they found
that while absolute PSA levels did not significantly differ between men with BPH and
PC, the rate of change of PSA was significantly greater in those subjects with PC. They
concluded that PSAV may act as an early biomarker for the development of PC [82]. Since
this initial study, there has been some debate on the value of PSAV for diagnosing PC or
providing a prognosis for PC in patients under AS [83,84]. However, there are studies that
indicate that PSAV has potential as a prognostic/predictive biomarker in patients treated
with RP [85–88] and RT [89,90]. The evidence thus far indicates that PSAV has better value
in the post-treatment setting rather than in the pre-treatment setting. PSADT has shown
promise as a predictive biomarker for PC detection on repeat biopsy, thus exhibiting the
potential it has in the avoidance of unnecessary biopsies [91]. Studies have also assessed
the clinical significance of PSADT before definitive therapy; here patients that exhibit
longer pre-operative doubling times have been shown to have a better prognosis following
treatment [92]. PSADT can additionally be used to monitor PC recurrence/progression
following curative therapy [53,93], with a doubling time of <3 months associated with
reduced survival times [93]. More recent work has demonstrated that PSADT can predict
the occurrence of metastasis [94–96]. Although measuring PSAV and PSADT can provide
additional information over the evaluation of total PSA alone, to date there is a lack of clear
evidence to endorse the sole use of PSA dynamics in the clinic. Further prospective studies
comparing the analysis of PSAV, PSADT and PSA are required [97].
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3.3. Molecular Forms of PSA
PSA can exist in multiple forms within the blood. PSA found in serum can be clas-
sified as either free PSA (fPSA) or complexed PSA (cPSA). Whereas fPSA is unbound to
carrier molecules/proteins, cPSA is bound to protease inhibitors (α1-antichymotrypsin,
α2 macroglobulin or α1-antitrypsin) [98]. Assays that can measure these molecular forms
can provide additional information over the assessment of total PSA levels [99–101]. fPSA
levels are generally expressed as a percentage of total PSA (%fPSA). In general, men with
PC have decreased levels of %fPSA when compared against men without PC [34]. As fPSA
levels tend to decrease with PC, it can distinguish PC from BPH [99]. Unfortunately, there
are limitations to the assessment of fPSA; this free form is less stable than complexed PSA
in the blood, meaning sample processing has to be done soon after collection [102]. Addi-
tionally, DRE and biopsy procedures lead to a rise in the amount of fPSA in the blood [103].
Increasing prostate volumes have also been shown to lead to increased %fPSA values; as
such, %fPSA is thought to only provide reliable data in patients whose prostate volume
is <40 cm3 [104].
Studies have suggested that the measurement of fPSA can be most beneficial in
patients whose PSA levels are between 4–10 ng/mL, with some reporting that the use
of fPSA can provide a diagnostic sensitivity of 95% and a specificity of 93%; however,
others have reported poorer corresponding values of 75% and 32% [105]. A meta-analysis
carried out to assess the accuracy of measuring %fPSA for the diagnosis of PC in men
with PSA concentrations ranging from 4–10 ng/mL demonstrated that this test had low
sensitivity and specificity. The authors concluded that %fPSA is neither sensitive nor
specific enough to be utilised by itself, and the results of these tests need to be combined
with additional diagnostic methods in helping to inform whether a prostatic biopsy is
required [105]. Oto et al. recently explored the potential of %fPSA when merged with
other factors, demonstrating that the combination of %fPSA with total PSA and age in a
predictive model increased the diagnostic potential of total PSA [106].
To circumvent some of the issues encountered with %fPSA, studies have investigated
the use of molecular forms of PSA in diagnostic assays, including intact PSA (iPSA) and
[2]proPSA [107]. The Prostate Health Index (PHI) assay, the 4-kallikrein panel (4Kscore)
and the Stockholm-3 (STHLM3) model are each multiplex tests that incorporate various
molecular forms of PSA. Each of these assays are detailed in the subsequent sections.
3.4. Prostate Health Index
The PHI assay was developed to aid the detection of clinically significant PC. It is a
score derived from total PSA, fPSA and [2]proPSA values using the formula ([2]proPSA/
fPSA) ×
√
total PSA [108]. [2]proPSA is a peptide precursor to mature PSA that is prefer-
entially produced in malignant cells [109]. The perceived advantage of this test is that it
allows clinicians to evaluate individual PSA parameters in combination with the overall
score produced. The chief use of PHI within the clinic is to lower the number of unnecessary
biopsies acquired from patients with PSA levels that are considered borderline, without
losing the detection of aggressive tumours.
The PHI test was approved in 2012 by the FDA for use in patients over 50, with
PSA readings between 4–10 ng/mL and a negative DRE. Studies have shown that PHI is
superior to %fPSA and total PSA in the detection of PC [110–116]. This greater accuracy
in the detection of PC was particularly apparent in patients with PSA levels between
2–10 ng/mL [113]. PHI has also shown increased predictive accuracy for clinically signifi-
cant/aggressive disease when compared against %fPSA and total PSA [116–120]. Between
15–45% of unnecessary biopsies can be avoided using the PHI test, depending on the cut-off
values used [121]. The capacity of PHI-density (determined by dividing the PHI score by
the prostate volume) to distinguish clinically significant PC has also been shown [122,123].
The combination of PHI with multi-parametric magnetic resonance imaging (mpMRI) has
also been assessed, with PHI helping to determine the need for re-biopsy and improving
the detection of clinically significant PC [123,124].
J. Pers. Med. 2021, 11, 664 10 of 37
The PHI score has been demonstrated to impact patient management in the clinic,
leading to biopsy deferrals when the patient PHI score was low and the decision to
carry out a biopsy when the PHI score suggested that there was an intermediate/high
probability of PC being present [125]. From a health-economic perspective, the cost-
effectiveness of including PHI in the decision-making process for whether a prostatic
biopsy is required has also recently been demonstrated [126,127]. As well as lowering the
number of unnecessary biopsies, the prediction of BCR following RP is another potential
use for the PHI test [128,129]. There are, however, some difficulties associated with the
use of this test in the clinic. While it has been shown that PHI is an effective tool for risk
stratification in both Asian and European populations, reports indicate that differing PHI
reference ranges should be employed for distinct ethnic groups [130]. Like fPSA, studies
have demonstrated that [2]proPSA also has some issues with molecular instability [131].
3.5. Four-Kallikrein Panel
Human kallikrein 2 (hK2) is a serine protease that shares 80% sequence homology with
that of PSA. Studies have indicated that hK2 may have a role in distinguishing between
patients with PC and those without malignant disease, while also having the ability to
predict stage, grade and BCR in those patients treated with RP [132]. Using serum samples
from the ERSPC trial, a prediction model was produced based on a panel of 4 kallikrein
markers: total, free and iPSA in combination with hK2 levels. Commercialised by Opko
Diagnostics, the 4-kallikrein panel (4Kscore), in conjunction with patient clinical data
(age, DRE and previous biopsy results), generates a risk of the presence of high-grade PC.
This model led to a better discrimination of high-grade PC when compared against total
PSA and clinical variables alone [133–136].
Like %fPSA and PHI, the primary aim of the 4Kscore is to reduce disease over-
detection by helping clinicians decide which patients require a biopsy. Its use is currently
recommended in men undergoing either an initial or a repeat biopsy. The results from a
large, prospective multi-institutional trial showed that the 4Kscore distinguished patients
that had a Gleason score ≥7 from those that scored <7. Using a 6% cut-off value, the
authors suggested that 30% of biopsies could be avoided whilst delaying a diagnosis
of high-grade PC in only 1.3% of patients [137]. Further studies have demonstrated
the potential of the 4Kscore to predict the presence of clinically significant PC [138–143].
As with PHI, the 4Kscore test has also been assessed when used in combination with
mpMRI, with results showing that the 4Kscore improved the prediction of high-grade PC
when utilised alongside mpMRI [144]. The ability of the 4Kscore to identify the presence of
aggressive cancers across multi-ethnic populations has also recently been exhibited, thus
demonstrating its wide clinical applicability [145].
Studies have established that use of the 4Kscore has the potential to significantly
influence clinician and patient decision-making processes, leading to a reduction in the
number of biopsies performed, while also increasing the likelihood of identifying aggres-
sive PC [146]. The capacity of the 4Kscore to significantly reduce costs while also enhancing
the quality of patient care has also been shown [147,148]. Other studies have investigated
the 4Kscore for its ability to predict distant metastasis; 4Kscores from patients assessed at
50 and 60 years of age can stratify men into two cohorts in terms of their risk of developing
metastatic disease 20 years following diagnosis [149].
3.6. The STHLM3 Model
Genome-wide association studies have produced convincing evidence for a genetic
predisposition for PC in some patients. Single nucleotide polymorphisms (SNPs) have
been described which account for around 30% of the hereditary risk for PC, offering novel
areas for exploration into the pathogenesis of this disease [150]. The combination of a
genetic score centred on these SNPs with PSA to improve the specificity of PSA testing
alone has been investigated [151,152]. STHLM3 is a risk-based model for PC screening that
combines 232 SNPs, a combination of plasma protein biomarkers (PSA, iPSA, fPSA, hK2,
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beta-microseminoprotein and macrophage inhibitory cytokine 1) and clinical variables
(family history, age, prostate exam and previous biopsies) [153]. Studies have found that
this model performed better than PSA alone for the detection of high-risk PC, exhibiting its
potential to improve PC diagnosis by significantly reducing the number of unnecessary
biopsies taken, while also preserving the same sensitivity to diagnose clinically significant
PC [153–157].
3.7. PSA Glycosylation
Glycans are saccharides that can be bound to lipids, proteins and other glycans
through glycosylation. Glycosylation is thought to be the most frequent post-translational
modification and is essential to nearly all biological processes that occur in the body [158].
Aberrant glycosylation is a widespread characteristic within cancer cells that has been
identified in most cancer types, and is often referred to as a “hallmark of cancer” [159].
A SNP that has an effect on PSA glycosylation has recently been linked to PC risk [160].
Developments in mass spectrometry technology have led to further research into glycan
structures on tumour-associated proteins; differing studies have assessed whether a glycan
signature on PSA may be utilised to improve its clinical efficacy [161]. The extent to which
a protein/lipid is glycosylated is dependent on the expression of specific glycosylation
enzymes in a cell, as well as the quantity of glycosylation sites present [162]; PSA contains
a single N-glycosylation site [161]. Variations in PSA glycosylation states have been
shown to occur in both PC cell lines [163] and in blood samples from patients with and
without PC [164]. So far, around 50 PSA glycoforms have been defined, with some of
these found to be present in aggressive PC. In particular, α2–3-linked sialic acid alterations
to PSA in clinical samples have gained the most interest from researchers. The ability
of α2,3-sialylated PSA to diagnose PC has been reported [165], with further studies also
demonstrating its potential to differentiate high-risk PC from low- and intermediate-risk
PC and BPH patients [166,167].
3.8. DNA Methylation
Epigenetic processes can affect the expression of genes, leading to alterations in
malignancy-associated phenotypes including angiogenesis, growth, invasion and mi-
gration. Numerous alterations in DNA methylation have been distinguished between
cancerous and benign prostate tissues [168]. As a result, aberrant DNA methylation is
an epigenetic change that has promise as a diagnostic or prognostic PC biomarker [169].
The Epigenetic Cancer of the Prostate Test in Urine (epiCaPture) is a DNA methylation
urine test for high-risk PC. It is designed to measure DNA hypermethylation within the
regulatory regions of six PC-associated genes (GSTP1, SFRP2, IGFBP3, IGFBP7, APC and
PTGS2) [170]. Increased methylation levels within epiCaPture genes have been shown to
be associated with higher PC aggressiveness. The authors concluded that epiCaPture could
be used as an adjunct to PSA, aiding in the selection of patients that should undergo a
prostatic biopsy [170].
4. Alternative Diagnostic Biomarkers to PSA
There are biomarkers other than PSA that have a role in the pre-diagnostic setting.
The ideal biomarker here should have the ability to increase the likelihood of identifying
clinically significant PC on biopsy tissues, while also leading to the avoidance of biopsies
in men who do not require one due to the absence of clinically significant PC. These
types of biomarkers can be categorised into those employed to decide who to biopsy
(SelectMDX, TMPRSS2-ERG score and the miR Sentinel test) and those utilised to choose
when to re-biopsy (ConfirmMDx, prostate cancer antigen 3 [PCA3] and the Prostate Core
Mitomic Test).
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4.1. SelectMDx
The SelectMDx assay is a urine-based test designed to give the probability of detecting
PC after a biopsy, in addition to the likelihood of low-grade versus high-grade disease.
SelectMDx is performed after prostatic massage, with mRNA levels of DLX1 and HOXC6
genes (reported to be good predictors for the detection of high-grade PC [171,172]) mea-
sured within the urine through qRT-PCR. DLX1 and HOXC6 gene expression levels are then
combined with clinical parameters (PSA density, age, DRE and family history information).
Van Neste et al. postulated that the use of this test could lead to a 42% decrease in the
total number of biopsies carried out, with a 53% reduction in the number of unnecessary
biopsies [172]. Further studies have shown that this test can help clinicians identify men
at risk of clinically significant PC, thus aiding the initial biopsy decisions and helping to
reduce the number of unnecessary biopsies [173–175]. Analyses have indicated that the use
of SelectMDx before proceeding to biopsy could lead to an increase in quality-adjusted life
years (a measure of disease burden that takes into account both the quantity and quality of
life lived) while also saving healthcare costs [176–178]. The SelectMDx test was included
in the 2020 National Comprehensive Cancer Network (NCCN) guidelines for the early
detection of PC. While there have been reports indicating that SelectMDx outperforms
other tests such as PHI in screening for the presence of high-grade PC before biopsy [179],
more recent papers have led to questions over the worth of the SelectMDx assay [180,181].
4.2. TMPRSS2-ERG Score
Chromosomal translocations are a common occurrence in cancer [182]. Tomlins et al.
identified candidate oncogenic genomic rearrangements based on outlier gene expression;
through this method, they discovered chromosomal translocations that lead to the fusion
of the androgen-regulated gene transmembrane protease serine 2 (TMPRSS2) and ETS
transcription factors (predominantly ETS-regulated gene [ERG]), also known as TMPRSS2-
ERG [183]. Experiments indicated that the androgen-responsive promoter of TMPRSS2
facilitated the overexpression of ERG in PC [183]. This chromosomal rearrangement has
been identified in pre-cancerous prostatic conditions (e.g., intraepithelial neoplasia) and
has been shown to be specific to PC [183–187]. TMPRSS2-ERG gene fusions occur in ~50%
of PCs [186,188,189]; in those cases that overexpress ERG, up to 90% will be positive for
the gene fusion [183,190–192].
Similar to the SelectMDx test, qRT-PCR can also be used to measure TMPRSS2-ERG
mRNA in urine samples following prostatic massage. Simultaneous assessment of PSA
mRNA allows a TMPRSS2-ERG score to be generated from the TMPRSS2-ERG mRNA/PSA
mRNA ratio. Studies have illustrated that the assessment of TMPRSS2-ERG gene fusions
in urine has the potential to predict the diagnosis of PC from subsequent prostatic biopsy
samples [188,193]. Others have shown a correlation between TMPRSS2-ERG gene fusion,
grade [194,195] and stage [196] at diagnosis, with analysis of the gene fusion also demon-
strated to have the ability to predict the risk of clinically relevant PC after a prostatic
biopsy [189]. Studies have additionally investigated whether TMPRSS2-ERG gene fusions
can be utilised to assess PC aggressiveness in patients undergoing AS, thereby having use
as a prognostic biomarker when assessed in prostatic tissues samples [190].
4.3. miR Sentinel Test
Exosomes and prostate-specific exosomes (prostatosomes) are small (30–150 nm) dou-
ble lipid membrane-bound extracellular vesicles that are generated within cells through
internal budding of multi-vesicular body membranes. For endosomal contents to be re-
leased from cells, they require endocytosis and fusion of their membranes with the cellular
plasma membrane. The contents of prostatosomes can be released into urine, semen and
blood, with these prostatosomes containing various molecules including proteins, lipids
and nucleic acids [197]. These substances not only play key roles in cellular signalling, but
have also been shown to be regulators of tumourigenesis and cancer progression, including
immune suppression, angiogenesis, cell migration and invasion [198]. As such, prostato-
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somes are a rich source of biomarkers for PC diagnosis and prognosis. In comparison to
men without disease, PC patients have increased numbers of serum-detected exosomes,
with reports indicating that these higher levels may also correlate with higher Gleason
scores [199]. Prostatosomal contents including PSA and TMPRSS2-ERG have also been
detected within urine-derived exosomes from PC patients [200].
The miR Sentinel test is a recently developed platform that analyses small non-coding
RNAs (sncRNAs) acquired from urinary exosomes [201]. This platform consists of three
different tests; the Sentinel PCa test (distinguishes patients with PC from those in which
there is no evidence of PC), the miR Sentinel CS test (differentiates patients that have PC into
those with low-risk disease and those with intermediate/high-risk PC) and the miR Sentinel
GH test (classifies patients with PC into those with low- and favourable intermediate-risk
disease and those patients with high-risk PC). Each of the tests demonstrated sensitivities
and specificities above 90%, highlighting their potential to diagnose and classify PC in a
non-invasive manner with great precision [201]. Further validation of these tests is required
in other independent patient cohorts and racially diverse patient groups.
4.4. ConfirmMDx
ConfirmMDx (MDxHealth, Inc) is an assay based upon DNA methylation and is
designed to separate patients that have PC from those with a true negative biopsy re-
sult. The methylation status of Glutathione S-Transferase Pi 1 (GSTP1), Ras association
(RalGDS/AF-6) domain family member 2 (RASSF2) and Adenomatous Polyposis Coli
(APC) are evaluated using this assay [202]. The assay requires a minimum of eight core
biopsy specimens obtained from specific prostatic regions. The advantage of using this
assay is that molecular DNA alterations in prostatic cells that are adjacent to PC lesions,
which would otherwise be diagnosed as histologically benign, can be identified. This is
a result of the “halo effect” that the tumour has on surrounding normal tissues [203].
A positive ConfirmMDx result in biopsy tissue that has been labelled as cancer negative
by a pathologist indicates that tumour cells were missed in the biopsy procedure. Thus
far, its use has been validated in two different studies [202,204], exhibiting the potential
ConfirmMDx has in helping to decrease the number of unnecessary repeat biopsies. In
those patients that produce positive results, DNA methylation intensities also aid in the
identification of men with high-grade disease [205]. While previous work was predomi-
nantly carried out in Caucasian men, recent work has demonstrated that this test is also
effective in African American patients [206]. The Prostate Assay Specific Clinical Utility at
Launch (PASCUAL) study (NCT02250313) is currently underway, examining the clinical
value of the ConfirmMDx test in urologic practices within the US.
4.5. PCA3
The prostate-specific PCA3 gene encodes a non-coding RNA that exhibits up to a
66-fold upregulation in prostatic tumours, with studies showing it to be present in >90% of
PC cases [207–209]. In light of encouragingly high sensitivity and specificity results from
tissues, numerous studies investigated the assessment of PCA3 levels non-invasively using
urine [209–211]. Through qRT-PCR, PCA3 mRNA can be readily measured in urine samples
following prostate massage. A PCA3 score is calculated from the PCA3 mRNA/PSA mRNA
ratio, multiplied by 1000. Analysis of PSA mRNA levels, as performed in the TMPRSS2-
ERG score assay, is required to control for the quantity of prostate epithelial cells in the
urine. A score below the cut-off of 25 is interpreted as a negative result (there is a decreased
likelihood of PC being present), with scores≥25 indicating an increased probability that PC
is present. However, there is debate over what PCA3 cut-off score should be used [212,213].
The PCA3 Progensa test was approved by the FDA in 2012 for use in suspect PC cases
with equivocal PSA/DRE/biopsy results. Studies have demonstrated that PCA3 has an
acceptable diagnostic accuracy and can help guide decisions on whether or not to carry out
an initial biopsy, thus reducing the number of unnecessary biopsies [214]. The addition
of PCA3 scores to individual risk estimation models, which included clinical factors, age
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and patient race, has been shown to improve PC stratification [215]. Wei et al. concluded
that PCA3 measurement can reduce the under-detection of high-grade disease in initial
prostatic biopsies, while also minimising the over-detection of low-grade PC in repeat
biopsies [215]. Other studies have also demonstrated that PCA3 can supplement PSA and
other clinical information to help give a more accurate prediction of the outcome from
repeat biopsies [216,217].
As with the previously discussed biomarkers, the combination of PCA3 score with
mpMRI has also been examined. The PCA3 score in men with a suspicious area for PC
after mpMRI was higher than that of patients with no suspicious regions post-mpMRI;
these results indicated that the PCA3 test could be used to pick those patients that should
be referred for an mpMRI scan [218]. The addition of the PCA3 score to mpMRI was also
shown to improve the predictive accuracy of mpMRI [219,220]. New methods for PCA3
detection are under development to enable PCA3 tests to be carried out in developing
countries and to allow the assay to be used as a point-of-care test [221–224].
Studies have indicated that PCA3 could be employed to influence decisions between
AS and more radical treatment options. It has been suggested that a threshold score of
20 could be used to identify men with clinically insignificant PC who would be eligible
for AS, while a threshold of 50 could identify men at higher risk of having clinically
significant PC who are good candidates for radical therapy [213]. However, the correlation
of PCA3 score and PC aggressiveness is under debate, with some studies exhibiting a
relationship between PCA3 score and Gleason score [225–229], whilst other do not [230,231].
Additionally, comparative studies indicate that PHI outperforms PCA3; PHI exhibited
increased accuracy for PC prediction in initial and repeat biopsies [232], with PHI also
superior in the detection of aggressive disease [233]. While it is improbable that PCA3 will
replace PSA as the frontline biomarker for PC, the measurement of both PCA3 and PSA
could lead to greater specificity for PC diagnosis.
4.6. Combined PCA3 and TMPRSS2-ERG Tests
Considering the significant heterogeneity seen within PCs, and the fact that not all PCs
will express PCA3 or possess TMPRSS2-ERG gene fusions, researchers have investigated
the use of multiplexed assays using both PCA3 and TMPRSS2-ERG gene fusions to improve
PC diagnosis [188,189]. The Mi-Prostate Score and ExoDx Prostate IntelliScore (EPI) test
are examples of these assays. The Mi-Prostate Score uses PCA3 and TMPRSS2-ERG urine
scores with serum PSA levels; this combination was shown to enhance the ability of serum
PSA to predict PC [234,235]. The EPI assay is an exosome-based urine assay which does not
require a prostatic massage. It assesses PCA3 and TMPRSS2-ERG mRNA levels, with the
SAM pointed domain-containing Ets transcription factor analysed for RNA normalisation.
The EPI assay has been suggested for use in men with increased PSA levels in order to give
a risk assessment for the presence of clinically significant PC at the initial biopsy [236,237].
The EPI test also has the potential to rule out the presence of high-grade disease using
repeat biopsy tissues [238]. Results from the EPI test have been shown to influence biopsy
decision making within the clinic [239]. Trials to confirm the performance of the EPI
assay in men presenting for initial (NCT04720599) and repeat (NCT04357717) biopsies are
currently underway.
4.7. Prostate Core Mitomic Test
Various cumulative genetic and epigenetic alterations within a cell contribute to the
process of cell transformation. Although some of these genetic changes lead to cancer
formation, early genetic alterations can lead to the growth of pre-neoplastic daughter cells
in a particular area of the tumour field. While changes in cellular morphology enable the
transformed cells to be diagnosed through histopathology, a population of pre-neoplastic
daughter cells may be present that would not be diagnosed using this method, illustrating
the concept of field cancerisation [240]. In PC, molecular field characterisation has been
described for gene expression profiles and genomic instability. One study demonstrated
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that a 3.4-kb mitochondrial genome deletion (3.4mt∆) had potential as a biomarker for
PC detection using biopsy samples. As a result of field cancerisation, the levels of 3.4mt∆
in clinical samples from malignant biopsy specimens were similar to the levels that were
acquired from samples close to the malignant tissue. The authors concluded that large-scale
mitochondrial DNA deletions may have use in the diagnosis of PC through their ability
to define benign, malignant and proximal to malignant tissue, thereby helping resolve
false from true-negative results [241]. The utility of this 3.4mt∆ in identifying men who
do not need a repeat biopsy has been shown [242]. The Mitomic Prostate Core Test was
subsequently developed for use in existing negative prostate biopsy tissue to assess if PC
was missed in the initial biopsy. Further studies have demonstrated the usefulness of this
assay in addressing sampling error issues encountered with prostate needle biopsies, with
the test contributing to the earlier detection of PC when clinicians included the test in their
re-biopsy decision-making process [243].
5. Biomarkers That Can Predict PC Aggressiveness
Definitive treatment for PC can lead to significant complications. Biomarkers that
give an indication of disease aggressiveness in patients who have already been diagnosed
would help clinicians decide who should be considered for AS and who should undergo
radical treatment. This would assist in the identification of patients who could benefit from
treatment, while also reducing the treatment risks and economic costs for those who are
unlikely to benefit.
5.1. Oncotype DX Genomic Prostate Score Assay
Predictive gene expression signature assays have been developed to help identify
cohorts of patients that gain specific benefits from certain therapies. Signatures of breast
cancer RT and chemotherapy response [244,245], and also treatment-predictive signatures
for lung cancer [246] are successful, clinically useful examples of these. The Oncotype
Dx assay, developed by Genomic Health, is a commercial gene signature assay that has
gained significant popularity for identifying cohorts of breast cancer patients that gain
benefit from adjuvant chemotherapy [247]. As a result of successful studies in breast,
the applicability of an adapted test to PC has been examined. The Oncotype DX Genomic
Prostate Score assay is carried out on prostatic biopsy tissue. It was designed to aid
treatment selection at the time of diagnosis in patients with low- or intermediate-risk
disease, enabling both patients and clinicians to make more informed choices between
AS and immediate radical treatment [248]. This test is based on the expression pattern of
12 genes that characterise four separate pathways known to be involved in PC development
and progression (proliferation, cellular structure/organisation, stromal interactions and
androgen signalling), along with five housekeeper genes. A final Genomic Prostate Score
(GPS) ranging from 0–100 is calculated. This GPS can provide predictive information
regarding the risk of identifying adverse pathology after RP (higher grade and stage
disease) [248–252], aids in determining the risk of PC recurrence after surgery [250], and can
also ascertain the risk of BCR and distant metastasis [250,252–254]. The cost-effectiveness
of the GPS assay in directing treatment decisions (AS versus immediate treatment) has also
been reported [255,256].
However, more recent work has highlighted some limitations of the Oncotype DX GPS.
Lin et al. tested the value of the GPS in predicting the presence of higher-grade disease
at surgery in low-risk PC patients who were treated with RP after initial surveillance.
They found that GPS did not significantly improve the stratification of risk for adverse
pathology over the measurement of PSAD and diagnostic Gleason Grade alone [257].
Another study showed that the histopathological features which are present in PC biopsies,
but are not usually reported, correlated with the GPS score. The authors suggest that more
comprehensive analysis of PC histopathology could be used as a substitute for some of the
information obtained from this test [258].
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5.2. Prolaris
The Prolaris assay, developed by Myriad Genetics, is a tissue-based test intended for
use in patients with newly diagnosed localized low- or intermediate-risk PC. This test is
designed to enable clinicians to better define a monitoring/treatment strategy for these
patients, identifying those who can be directed safely to AS and those that would benefit
from treatment intensification. It is based on the expression patterns of 31 genes involved
in cell cycle progression (CCP), in addition to 15 housekeeper genes. Overexpression of the
CCP genes suggests that the cancer cells are rapidly dividing, while decreased expression
signifies slower growth and a less aggressive cancer [259]. The Prolaris score or CCP score
is reported on a scale ranging from 0 to 10, where higher scores are indicative of a more
aggressive tumour [260]. The CPP score has been shown to give significant pre-treatment
prognostic information that can be used to help determine which patients can be managed
conservatively [261,262], with additional studies demonstrating that this assay has the
ability to provide prognostic information for men undergoing either RP [259,263–266] or
RT [267]. Higher CCP scores have also been shown to be linked with a higher risk of
systemic disease [268] and can predict metastasis after either RT or surgery [269]. Results
from the Prolaris assay have influenced therapy decisions within the clinic; there has been
an increase in the proportion of patients undergoing AS in those that have been classified
as low-risk by the Prolaris test, and intensification of treatments in those whose test results
indicted the presence of more aggressive cancer [270–272]. While the potential benefits of
the Prolaris assay have been exhibited, its value is limited by the retrospective nature of
many of the studies performed; largescale, prospective trials are needed [260]. Additionally,
the cost-effectiveness of the Prolaris test is still under debate [273,274].
5.3. ProMark
The ProMark quantitative immunofluorescence test was developed in an attempt to
give clinicians the ability to predict PC aggressiveness, irrespective of whether biopsy cores
came from low- or high-grade tumour regions, therefore accounting for sampling variation
and PC heterogeneity. In a study carried out by Shipitsin et al., tissue regions with the
lowest and highest grades were isolated in prostatectomy samples from the same patients;
a panel of protein biomarkers was identified that predicted PC aggressiveness and outcome
from both low- and high-grade areas [275]. This test is based on the expression patterns
of eight proteins (DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, pS6 and YBOX1) with
known functions related to proliferation, tumour-associated signalling pathways and stress
response, altogether providing information about tumour aggressiveness from formalin-
fixed, paraffin-embedded (FFPE) tissues [276]. The primary function of the ProMark test is
to separate candidates for AS from those that require RP, in addition to ascertaining those
patients with favourable/non-favourable pathology. Although not yet validated, the test
has the potential to accurately stratify low- and high-risk PC patients using biopsy samples.
5.4. Decipher
The Decipher test, developed by GenomeDx, is a genomic signature that was devel-
oped to help identify aggressive PC and improve the prediction of early PC metastasis
using information from the primary tumour after RP. This test analyses the RNA expression
levels of 22 genes (involved in cellular differentiation, proliferation, cell cycle, motility,
adhesion, immune modulation and androgen signalling) detected in the primary tumour
and was developed by modelling differential RNA expression patterns in early metastatic
tissues versus controls [277]. The final Decipher score ranges from 0–1, with higher scores
(0.61–1) associated with a higher probability of metastasis. This genomic classifier has
gained interest for its use in patients after RP and can predict both the 5- and 10-year
metastatic risk [278–280]. A recent meta-analysis conducted by Spratt et al. showed that
Decipher can improve the prognostication of patients post-RP; the 10-year cumulative
metastatic incidence rates after RP were 5.5%, 15.0% and 26.7% for patients that were
deemed low-, intermediate- and high-risk using the Decipher test [281]. These results
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are supported by another study showing that transcriptional profiles can stratify patients
into cohorts, separating those who will develop metastasis after RP from those who will
not [282]. A recent study highlighted how Decipher, in combination with standard clini-
copathologic variables, can lead to better risk-stratification when combined with current
guidelines [283]. While the test was developed from the analysis of primary tissue after RP,
the ability of the Decipher test to predict metastasis using biopsy tumour tissue has also
been shown [284,285].
The potential of Decipher to predict BCR after surgery has also been established [286].
Patients exhibiting BCR after RP often have varied outcomes and thus present a manage-
ment dilemma to clinicians; initial studies showed the ability of the Decipher test to predict
metastasis in these patients, exhibiting its potential to identify men who require earlier ini-
tiation of treatment after BCR [287]. More recent studies have demonstrated that Decipher
can be used to predict the absence of adverse pathology in low- and intermediate-risk PC
patients, with the authors suggesting that Decipher may have a role in predicting which
newly diagnosed patients are good candidates for AS [288]. Furthermore, Decipher scores
have been shown to have potential in determining those patients who are most suitable
for RT following RP [289,290]. The ability of the Decipher test to alter clinical decisions
regarding the use of adjuvant treatments has been reported [291,292]. Altogether, data from
several studies has demonstrated the clinical usefulness of the Decipher test, exhibiting its
potential to significantly improve the personalisation of PC treatment [293].
5.5. Ki67
Ki67 is a nuclear protein related to ribosomal RNA synthesis. This protein is used
as a marker for tumour proliferation, with analysis of Ki67 levels typically carried out
through immunohistochemistry on FFPE tissues. Staining is described as the percentage of
Ki67-positive cells within the total number of cancer cells present. Ki67 has been shown
to be a prognostic and predictive biomarker in breast cancer [294]. Within PC, a higher
percentage of Ki67-positive cells seems to have prognostic value for BCR, distant metastasis
and survival in patients treated with either surgery or RT [295–298]. A recent meta-analysis
incorporating 21 studies, comprised of 5419 patients, demonstrated that after curative-
intent treatments, high Ki67 expression was a poor prognostic factor for disease-specific
survival, disease-free survival, rate of distant metastases and overall survival. The authors
concluded that Ki67 should be integrated into the clinic for use in PC patients [299].
However, despite the fact that Ki67 is one of the best validated prognostic markers that
has been in use for over 30 years, some maintain that this protein is not yet ready for use
in the clinic. High levels of variability in scores have been observed between different
cohorts of PC patients, with scores ranging from 2.1% to 28% [300]. This issue seems to be
particularly relevant in high-risk patients, in whom significant inter- and intra-prostatic
Ki-67 heterogeneity has been reported [301]. The cut-offs used to distinguish a negative
from a positive score also differ greatly between studies; this lack of standardisation across
pathology laboratories contributes to the limitations of Ki67 as a PC biomarker [302].
5.6. MicroRNAs
MicroRNAs (miRNAs) are single stranded, small non-coding RNA molecules (~20 nu-
cleotides in length) that function as post-transcriptional gene regulators through their
ability to bind to complementary base pairs within specific mRNAs [303]. Alterations
in miRNA profiles have been identified in PC. It has been suggested that miRNAs can
regulate PC stem cells, cellular proliferation and differentiation, thereby influencing dis-
ease development and progression [304,305]. Studies showing that miRNAs are present in
human blood in a very stable form [306] led to the development of miRNA signatures from
blood samples in an attempt to improve the accuracy of PC diagnosis and prognosis. One
such study identified a panel of 14 miRNAs, known as the miR risk score, which was able
to discriminate Gleason grade and predict BCR following RP [307]. A further study showed
that miR-16, miR-195 and miR-148a expression was correlated with Gleason scores ≥8, and
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that these three miRNAs could stratify patients into intermediate- and high-risk Gleason
scores [308]. Several PC studies have also investigated miRNA signatures from urine
samples to differentiate healthy patients or those with BPH from those with PC [309,310]
5.7. Phosphatase and Tensin Homolog
Phosphatase and tensin homolog (PTEN) is a well characterised tumour suppressor
gene involved in the regulation of the phosphatidylinositol 3-kinase (PI3K) pathway. Loss
of function of PTEN and the resulting de-regulation of the PI3K pathway is regarded as
one of the most common driver events in PC development [311]. Loss of PTEN function
has been shown to occur in ~40% of PC cases, especially in those with TMPRSS2-ERG gene
fusions [312]. Although immunohistochemistry is typically used to evaluate PTEN loss,
fluorescence in situ hybridisation (FISH) can be utilised where ambiguous immunohisto-
chemistry results have been obtained [313]. Several studies have examined the use of PTEN
loss as a biomarker in PC; one study suggested that patients exhibiting PTEN loss in Glea-
son score 6 tumours, identified from biopsy tissue, were at higher risk of having their score
upgraded using samples obtained at RP [314]. Other investigations have demonstrated
that loss or even just a decrease in PTEN expression is correlated with higher Gleason
scores, more advanced disease stage, metastasis, BCR and disease recurrence [315–319].
Furthermore, shorter survival times have been reported in advanced PC with PTEN loss
when treated with abiraterone acetate [320]. Apart from the removal of the tumour sup-
pressive function, PTEN loss has also been associated with AR signalling suppression and
inhibition of androgenic genes [321]; this may drive PC into an androgen-independent
phenotype, ultimately reducing the efficacy of ADT.
6. Predictive Biomarkers
Predictive biomarkers indicate the likelihood of a particular treatment providing a ther-
apeutic benefit. These biomarkers can therefore be used to aid treatment selection, enabling
the identification of patients that are most likely to gain benefit from a particular therapy,
whilst sparing others from the side effects of ineffectual treatment. Here, we provide an
overview of a selection of predictive biomarkers that are currently being researched.
6.1. Post-Operative Radiation Therapy Outcomes Score
Although RT post-RP can significantly improve clinical outcomes, recent work does
not support the routine administration of adjuvant RT post-RP [322]. It has been suggested
that certain patient cohorts are more likely to gain benefit from its use; identification of
these patients will improve their outcome while sparing the risk of developing radiation-
induced side effects in those unlikely to gain a clinical benefit. Unfortunately, as of yet no
gene signature has been clinically validated to predict RT response in PC patients. To begin
to address this clinical issue, one study has developed and initially validated a 24 gene
signature to predict RT response. This Post-Operative Radiation Therapy Outcomes Score
(PORTOS) was developed using gene expression data from prostatic adenocarcinomas
in patients who received a RP with or without adjuvant RT. Results demonstrated that
the distant metastatic rate at 10 years for patients with a high PORTOS who received
RT was lower than that observed for patients with a high PORTOS who did not receive
RT (4% vs. 35%). While the authors suggested that PORTOS could be used to predict
outcomes post-RT, thereby identifying which patient cohort should receive RT, they also
demonstrated that other prognostic tools such as Decipher and the CCP score did not
predict RT response [323].
6.2. DNA Repair Defects
Both pre-clinical and clinical reports indicate that DNA damage response pathways
have a significant part to play in the progression of PC [324]. DNA repair defects are
thought to be relatively frequent in more advanced PC, with genetic abnormalities that
inhibit DNA repair shown to be present in mCRPC tumours [325]. It is thought that the
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identification of alterations in DNA repair pathways may be predictive of response to
certain therapies. Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) has
a part to play in numerous aspects of DNA repair. PARP inhibitors are a class of anti-
cancer agents that work through inducing synthetic lethality; this is a process where the
PARP inhibitor, in combination with either an inherent genetic defect or another therapy
(such as RT), cause irreparable DNA damage and cell death [326]. PARP inhibitors initially
demonstrated their potential as an anti-cancer therapy in patients with BRCA1/2 mutations
and they have become a standard treatment for patients suffering from ovarian and breast
cancer. Olaparib and rucaparib are PARP inhibitors that have been approved by the FDA
for the treatment of mCRPC [326]. The identification of DNA repair defects in mCRPC
patients has been shown to predict response to PARP inhibitors; however, not all DNA
repair defects have the same impact on the efficacy of treatment [327]. While the majority
of data for PARP inhibitors has been generated for mCRPC patients, there will be interest
among the scientific and clinical communities on the results of studies concentrating on
earlier disease stages.
6.3. Androgen Receptor
The androgen receptor (AR) is a nuclear hormone receptor transcription factor that
plays a significant role in the function of prostatic cells through its ability to bind sex
steroids and control transcription of androgen-dependent genes [328]. ADT is a common
treatment for PC; however, although nearly all PCs respond to this treatment in the begin-
ning, tumour recurrence and progression into castrate-resistant prostate cancer (CRPC)
typically occurs [329]. While the progression of androgen-dependent PC to CRPC likely
involves various mechanisms, AR and its signalling have been shown to play important
roles in disease development, including the acquisition of acquired resistance to various
ADT drugs [330]. Within CRPC, AR alterations have been shown to occur through over-
expression of wild-type or constitutively active variants (AR-Vs), gene amplification and
mutations [331]. AR-Vs, generated from alternative splicing or gene rearrangements, have
the ability to regulate transcription. Although these AR-Vs are truncated proteins that lack
the AR ligand-binding domain, they still have functional DNA-binding and transcriptional
activation domains, resulting in ligand-independent constitutive activation that is not
constrained by anti-androgen treatment [331]. The AR-V7 form is frequently detected in
mCRPC and has gained clinical interest for its use as a biomarker to help select the most
appropriate treatments [332]. A crucial decision in mCRPC management is when to ad-
minister an AR signalling inhibitor or a taxane; studies have shown that AR-V7 expression
is associated with the resistance of mCRPC to enzalutamide and abiraterone [333–335],
while its expression also appears to correlate with increased response to taxane chemother-
apies [336]. AR-V7 in CRPC patients can be detected within both prostatic tissue samples
and circulating tumours cells (CTCs) [332,337]; however, conflicting findings have been
observed between CTC AR-V7 results and AR-V7 protein expression in biopsy samples
acquired from the same patient [338]. The OncotypeDX AR-V7 Nucleus Detect (Epic Sci-
ences) and the AdnaTest AR-V7 assay (Qiagen) have been developed for the assessment of
the constitutively active AR variant in CTCs.
6.4. Immune Checkpoint Inhibition
Monoclonal antibodies targeting immune checkpoint inhibitors are being considered
as a new therapeutic strategy for the treatment of mCRPC. Immune checkpoint inhibitors
(cytotoxic T lymphocyte-associated protein-4 (CTLA-4) receptor and programmed death-1
(PD-1) receptor) are present on T lymphocytes; these receptors act as negative regulators of
the immune response, setting a balance between an effective immune response (including
the response of the immune system to cancer cells) and tolerance to antigens produced
by normal cells of the body [339]. The over-expression of ligands for these receptors on
cancer cells (leading to the activation of immune checkpoint inhibitors and the inactivation
of immune cells) has been observed in PC, contributing to the escape of these cancer cells
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from the host’s immune response [339]. The concept that the CTLA-4 and PD-1 receptors
might be utilised by cancer cells to avoid the immune system led to the development of
monoclonal antibodies that could inhibit these receptors, with the hope that targeting
them would lead to a more effective anti-tumour response from T lymphocytes. Although
some studies have demonstrated that Ipilimumab (an anti-CTLA-4 monoclonal antibody)
and Nivolumab (an anti-PD-1 monoclonal antibody) are effective treatments for advanced
PC [340,341], others have shown mixed results from the use of these agents [339]. It is
thought that only certain patients are eligible for immunotherapy: those presenting with
either high expression levels of CTLA-4 and PD-1 receptor ligands on cancer/stromal
cells, or increased amounts of the immune checkpoint inhibitor receptors on immune cells.
As such, it is believed that these proteins may act as biomarkers that could predict/monitor
immunotherapy effectiveness [342,343].
Research into the predictive potential of genomic biomarkers for immunotherapy
is also ongoing. Tumour mutational burden (TMB) can be used to describe the number
of mutations in a tumour cell. Patients suffering from advanced PC have been shown
to exhibit higher levels of TMB [344,345]. While the prediction of PC patient reaction
to immunotherapy is complex, increased levels of TMB have been linked to better re-
sponse [346]. It is believed that a higher TMB causes the production of increased levels of
neoantigens (mutated antigens that are only expressed by cancer cells), which leads to a
higher probability of an effective T-cell-dependent anti-cancer response [347]. Additional
genomic predictive biomarkers for response to immunotherapy have also recently been
identified; mutations within cyclin-dependent kinase 12 (CDK12), a tumour suppressor
protein with roles connected to genomic stability [348], have also been demonstrated to
lead to the creation of neoantigens [349]. It is thought that CDK12-altered PCs may respond
favourably to immune checkpoint inhibitors [350].
7. Limitations and Future Perspectives of PC Biomarker Assays
The function of the prostate is to perform as a secretory gland, secreting proteins
including PSA into seminal fluid. As such, liquid-based biomarkers, such as those acquired
from the blood or urine, are well placed to act as PC-specific biomarkers. The identification
of biomarkers in liquid biopsies has significant advantages over tissue-based techniques as
they can be obtained easily in a less invasive manner. Liquid biopsies can also be routinely
taken pre-, post- or on-treatment, meaning continual patient monitoring can be achieved,
while tissue biopsies give only a limited snapshot of the tumour. Tumour heterogeneity is
a significant problem for tissue-based biopsy tests, as results can only be determined from
the area that the tissue samples are acquired from [351,352]. Liquid biopsies, in comparison,
have the potential to give a comprehensive view of both primary and metastatic cancers.
Urine samples in particular have specific advantages in PC management; as a result of
the proximity of the bladder to the prostate, urine can contain biomarkers that reflect PC
development and progression.
Of the liquid-based assays, PSA is the best validated and most widely used biomarker
employed by clinicians. This is likely to remain the case for the present, despite limitations
associated with its use. To overcome some of these issues, studies have examined the use
of different PSA parameters/dynamics. The combination of PSA with adjunct tests is also
being studied in an attempt to enhance the diagnostic specificity and prognostic potential
of PSA. Of the tissue-based biomarker tests discussed, Oncotype DX Prostate, ProMark,
Decipher and Prolaris are the best validated thus far. While these tissue-based biomarker
assays have the potential to influence the management of PC patients, there are a number of
issues that are currently restricting their use: (i) Direct comparison of Oncotype DX, Prolaris
and Decipher to one another has shown that prognostic outcomes can differ depending on
the test used [353,354]. (ii) Many of these assays were developed and initially validated in
cohorts of patients who were mostly white European or white American men, with limited
initial research performed into the value of these tests in African American men, who are
recognised as having poorer outcomes. While some of the assays have been validated
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and shown to provide benefit in diverse racial groups [250,355–357], racial differences
across the gene expression panels used for PC prognosis have been identified [358]. (iii)
Lastly, the clinical usefulness of these multigene signatures has yet to be prospectively
validated in a randomised clinical trial. Regardless of these shortcomings, present NCCN
recommendations assert that Prolaris, Decipher, ProMark and Oncotype DX Prostate can
be used for risk stratification in patients with either low- or favourable intermediate-risk
PC [359].
8. Conclusions
Significant advances continue to be made in the field of PC. Although the widespread
use of PSA levels for PC diagnosis and management led to criticisms of over-diagnosing
and over-treating patients, its use undoubtedly paved the way for investigations into
more specific PC biomarkers. The biomarkers discussed in this review have the potential
to contribute immensely to PC patient management by (i) cutting down on unnecessary
biopsies, (ii) enhancing patient risk assessment and therefore treatment selection and (iii)
leading to more selective treatments for PC patients with higher-risk disease.
For any biomarker-based assay to become translated into the clinic and used routinely,
studies need to demonstrate specificity, sensitivity and their potential to improve upon
current clinical practices. That said, PC biomarker research holds much promise; linking
novel PC-specific biomarkers with other techniques, such as clinical data, PSA levels,
Gleason grading, disease staging and imaging would undoubtedly help improve the
management of PC patients. Ultimately, we need implementation of many of the assays
discussed into well designed randomised clinical trials in order to validate them; hopefully
it is only a matter of time before this can be achieved.
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